Trial · NCT07559045
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07559045, Phase 2, Recruiting, Second Affiliated Hospital of Zunyi Medical University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma. Trials, record NCT07559045. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07559045
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
- NCT number
- NCT07559045
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 92 participants, estimated
- Lead sponsor
- Second Affiliated Hospital of Zunyi Medical University
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
- Interventions
- Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy), Weekly Paclitaxel plus Cisplatin or Carboplatin (Concurrent Chemotherapy)
- First posted
- 2026-04-30
- Last updated
- 2026-04-30
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Response (CR) Rate at 3 Months After Radiotherapy (Investigator-Assessed) | 3 months after completion of radiotherapy | Proportion of patients achieving complete response (CR) per RECIST 1.1, assessed by investigators at 3 months after completion of radiotherapy |
| Primary | 1-Year Progression-Free Survival (PFS) Rate | 1 year after randomization | Proportion of patients alive and without disease progression at 1 year after randomization |
| Secondary | Overall Survival (OS) | Up to 3 years after randomization | Time from randomization to death from any cause |
| Secondary | Progression-Free Survival (PFS) | Up to 3 years after randomization | Time from randomization to first documented disease progression or death from any cause, whichever occurs first |
| Secondary | Duration of Response (DOR) | Up to 3 years after randomization | Time from first documentation of objective response (CR/PR) to first documented disease progression or death |
| Secondary | Objective Response Rate (ORR) | Up to 3 years after randomization | Proportion of patients achieving CR or partial response (PR) per RECIST 1.1 |
| Secondary | Local Regional Failure-Free Survival (LRFS) | Up to 3 years after randomization | Time from randomization to first local or regional recurrence or death |
| Secondary | Distant Metastasis-Free Survival (DMFS) | Up to 3 years after randomization | Time from randomization to first distant metastasis or death |
| Secondary | Incidence of Treatment-Emergent Adverse Events (TEAEs) | From first study treatment to 30 days after last treatment | Incidence and severity of TEAEs (graded per CTCAE 5.0) during treatment and follow-up |
| Secondary | EORTC QLQ-OES18 Symptom Score Change | Baseline, 3 months, 6 months, 12 months after radiotherapy | Change in esophageal cancer-specific symptom score as assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Oesophageal 18 (EORTC QLQ-OES18) from baseline to post-treatment follow-ups. The scale ranges from 0 to 100, with higher scores indicating more severe symptoms and worse quality of life. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07559045
GET https://conductscience.org/api/trials/v1/NCT07559045/registered